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Methylmalonic aciduria (MMAuria), caused by deficiency of
methylmalonyl-CoA mutase (MUT), usually presents in the
newborn period with failure to thrive and metabolic crisis lead-
ing to coma or even death. Survivors remain at risk of metabolic
decompensations and severe long term complications, notably
renal failure and neurological impairment. We generated clini-
cally relevant mouse models of MMAuria using a constitutive
Mut knock-in (KI) allele based on the p.Met700Lys patient
mutation, used homozygously (KI/KI) or combined with a
knockout allele (KO/KI), to study biochemical and clinical
MMAuria disease aspects. Transgenic Mutki/ki and Mutko/ki
mice survive post-weaning, show failure to thrive, and show
increased methylmalonic acid, propionylcarnitine, odd chain
fatty acids, and sphingoid bases, a new potential biomarker of
MMAuria. Consistent with genetic dosage, Mutko/ki mice have
lowerMut activity, are smaller, and show highermetabolite lev-
els thanMutki/ki mice. Further,Mutko/ki mice exhibitmanifesta-
tions of kidney and brain damage, including increased plasma
urea, impaired diuresis, elevated biomarkers, and changes in
brain weight. On a high protein diet, mutant mice display dis-
ease exacerbation, including elevated blood ammonia, and cat-
astrophic weight loss, which, in Mutki/ki mice, is rescued by
hydroxocobalamin treatment. This study expands knowledge of
MMAuria, introduces the discovery of new biomarkers, and
constitutes the first in vivoproof of principle of cobalamin treat-
ment inmut-type MMAuria.
Methylmalonyl-CoA mutase (MUT)2 is a homodimeric
enzyme that catalyzes the reversible isomerization of L-methyl-
malonyl-CoA to succinyl-CoA by using vitamin B12 (cobala-
min, Cbl) in the cofactor form (5-deoxyadenosylcobalamin,
AdoCbl). In this anaplerotic reaction, several metabolic path-
ways, including the breakdown of branched chain amino acids,
odd chain fatty acids, and the side chain of cholesterol, con-
verge on the propionate pathway. The vital importance of this
enzyme is demonstrated by the severe inborn error of metabo-
lism methylmalonic aciduria (MMAuria), which is caused by
mutations in the MUT gene (mut-type MMAuria, OMIM no.
251000) or by defects of AdoCbl synthesis. Dysfunction of
MUT leads to an accumulation of methylmalonic acid (MMA),
2-methylcitrate (2-MC), propionylcarnitine (C3), and other
metabolites in body fluids and tissues (1, 2). Although the clin-
ical symptoms observed in mut-type MMAuria patients are
variable, they often present in the newborn period with ketoac-
idosis, lethargy, and failure to thrive, leading to coma or even
death if untreated. In surviving patients, the chronic course
involves organ-specific complications, themost common being
neurological impairment and chronic kidney disease, manifest-
ing as tubulointerstitial nephritis and renal tubular acidosis.
End stage renal disease, occurring as early as the second decade
of life in patients with severe MMAuria, is frequently seen
(3–6). In addition to symptomatic care, there are a few rational
treatment approaches, including reduction of protein intake,
carnitine andCbl supplementation to decrease the flux through
the propionate pathway, and the formation of toxicmetabolites
(6). Although this treatment appears to partly improve meta-
bolic control in some cases,most patients still suffer severe long
term complications.
The first effort to generate a mouse model of mut-type
MMAuria was made in 2003, when a Mut knockout (KO)
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model on C57BL/6 background resulted in neonatal lethality of
all homozygous (KO/KO) pups (7). Later, Peters et al. (8)
expressed varying copy numbers of the intact human MUT
locus on theKObackground anddemonstrated a copynumber-
dependent rescue of the KO lethality. They also developed
another transgenicmodel containing an introduced stop codon
on the human MUT locus crossed to the KO background,
resulting in a severe MMAuria phenotype (9). In 2009, Chan-
dler et al. (10) generated a Mut-KO mouse on the modified
((C57BL/6X129Sv/Ev)  FVB/N) background, resulting in
some KO mice surviving the neonatal period, although nearly
all died within 25 days (11). Using this KO model, they applied
adeno-associated virus-mediated gene therapy (11, 12) and sta-
ble transgenic Mut expression restricted to the liver (13) to
provide a long term rescue of lethality. However, whereas these
models have proven to be useful to study some aspects and
rescue of disease, no model to date has been able to provide an
accurate depiction of the patient situation. Neonatal or early
lethality hamper long term follow-up studies and the under-
standing of chronic disease manifestation, whereas transgenic
rescue of Mut does not resemble the pathologic situation,
where a patient carries the same genetic defect in all cells.
To devise a model of MMAuria reflective of the patient situ-
ation using a known human mutation and amenable to the
study of the long termdisease course, we opted to knock-in (KI)
a hypomorphic allele based on a patient missense mutation.
From our previous in-depth MUT missense mutation charac-
terization (14), we identified p.Met700Lys (c.2099TA human
cDNA; p.Met698Lys in mouse) as an ideal candidate for this
allele because of the residual enzymatic activity and in vitro
response to hydroxocobalamin (OHCbl) found inMUTprotein
carrying this mutation. p.Met700Lys has been detected
heterozygously in four MMAuria patients in conjunction with
severe mutations (15, 16), but at least three of these patients
have had an intermediate disease course with a relatively later
age of onset (between 14 days and 6 months) (16), supporting
the potential of this mutation to cause moderateMMAuria. To
assess the effect of genetic dosage on the phenotype and to
generate amore severe diseasemodel, the newKImutationwas
combined with a KO allele (7). Here we present a thorough
characterization of these newly generatedMutki/ki andMutko/ki
mouse models, which survive long term and at the same time
recapitulate the key biochemical and clinical features of
MMAuria.
Results
In Vitro Characterization of the p.Met698Lys Knock-in
Allele—To characterize the selected KI mutation, we tested the
biochemical properties of the human mutation p.Met700Lys
(hs-p.Met700Lys) and the equivalent mutation in mouse
(mm-p.Met698Lys). Separate constructs incorporating each
allele were overexpressed in human fibroblasts carrying a
homozygous null allele of MUT to determine enzyme activity
and kinetics. In both, the residual activity was reduced to a few
percent ofwt (Table 1)with an almost 100-fold increasedKm for
AdoCbl (Table 1). These nearly identical biochemical results
for the human and mouse equivalent mutations led us to
conclude that the mm-p.Met698Lys mutation would be
expected to produce an intermediate phenotype of MMAu-
ria, similar to its hs-p.Met700Lys counterpart.
Generation of KI Allele and Initial Characterization—To
generate the knock-in p.Met698Lys mutation, a targeting vec-
tor was designed to replace thymine with adenine at position
c.2093 of Mut (based on NM_008650.3). The construct (Fig.
1A) was used for embryonic stem cell (C57BL/6-derived) tar-
geting, and a positive clone was confirmed by Southern hybrid-
ization (Fig. 1B), which was used for blastocyst injection.
Screening for positive germ line transmission was done by PCR
genotyping (Fig. 1C, upper panel). Additionally, Mutko/ki mice
were generated as a second disease model by crossing the pre-
viously established Mutko/wt mice (7) with our Mutki/ki mice
and followed by PCR genotyping of the KO allele (Fig. 1C, lower
panel).
To determine the direct consequences of the missense
change on Mut transcript, stability, and function, we investi-
gatedMut expression and activity in various tissues. Inwtmice,
we found Mut expression to be lower in brain than in liver or
kidney (Fig. 1D), similar to previously published results (17).
The KI allele did not result in an appreciable decrease of Mut
transcript levels in all tissues tested; however,micewith oneKO
allele had50% ofMut transcript levels comparedwithwt (Fig.
1E), likely indicative of nonsense-mediated decay. At the pro-
tein level, the amount of the homozygousMutki/ki protein was
significantly reduced compared with controls, suggesting an
unstable mutant protein, whereas the KO/KI Mut protein
showed similar reduction (Fig. 1F). Mut activity from wt mice
significantly varied among tissue types, with the highest activi-
ties in kidney, liver, and heart (Fig. 1G). Activities from KI/KI
and KO/KI mice were greatly decreased in all of the tissues
tested (Fig. 1H), comparable with the in vitro measurements
(Table 1). Furthermore, a gene dosage-dependent decrease of
enzyme activity was identified, with Mutko/ki activity slightly
lower than Mutki/ki in most tissues (Fig. 1H). As expected,
50% of residual activity was maintained in the Mutki/wt and
Mutko/wt animals, reflecting the activity of the remaining wt
allele (Fig. 1H).
Gene Dosage-dependent Biochemical and Clinical Phenotype
in Mutki/ki and Mutko/ki Mice—Mice homozygous for the tar-
geted point mutation (Mutki/ki) were viable and, when crossed
with heterozygous Mutki/wt mice, reproduced at the expected
Mendelian ratio of 50% per genotype (51% Mutki/wt, 49%
Mutki/ki, litters 33). Breeding ofMutko/ki also resulted in via-
ble animals and displayed the expectedMendelian distribution
TABLE 1
Human andmousemutant proteins show similar enzyme parameters
when expressed in amut0 patient cell line
Mean enzyme activities weremeasured in fibroblast homogenates after overexpres-
sion of the respective constructs. Mutant values were calculated in relation to their
wt counterparts and normalized to the percentage of residual activity of the respec-
tive wt (set to 100%). Km values for AdoCbl were determined by measuring MUT
activity with increasing concentrations of AdoCbl ranging from 0.0025 to 50 M in
the same homogenates as above. The displayed numbers represent mean values
S.D.
Human Mouse
wt p.M700K wt p.M698K
Activity 100.0 22.4 3.46 0.38 100.0 32.1 6.04 0.24
Km 2.59 0.87 575.6 46.0 8.70 0.02 463.6 37.3
Phenotype and Treatment Study inMMAuriaMouseModel
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of the genotypes (51% Mutko/ki, 49% Mutki/wt, litters  36).
Mice of both genotypes survived over 1 year, allowing us to
monitor long term development. At early stages of life,Mutki/ki
and Mutko/ki mice were largely indistinguishable from their
heterozygous littermates (Mutki/wt) and wt control mice. How-
ever, after the age of 100 days in females and 150 days in
males (Fig. 2A), mice of both genotypes showed signs of signif-
icant growth retardation. The difference in body weight
between littermate control (Mutki/wt) andMutko/ki femalemice
was 30% after1 year (Fig. 2A), whereas food intake remained
constant (e.g. relative food intake at the age of 218 days in
Mutki/wt was 0.079 grams of chownormalized to bodyweight in
FIGURE 1.Generation of KI allele and initial characterization. A, based on thewtmouseMut gene, a targeting construct was generated to replace theMut
gene region spanning from introns 8 to 12 (shaded in gray), consisting of long and short arms of homology, as well as an insert with the missense mutation
(p.Met698Lys) and a neomycin cassette (neo, green arrow) flanked by FRT sites (vertical green triangles). Homologous recombination and Flp deletor breeding
resulted in the final targeted KI allelewith themutation and one remaining FRT site. Exons are represented by red trianglesor boxes.Arrowsmarked fwd and rev
indicate forward and reverse genotyping primers, respectively. B, Southern blotting of targeted clone 12H5. C, upper panel, genotyping PCR of ear biopsy DNA
for the KI allele with forward and reverse primers depicted in A. The asterisk indicates an additional heterodimer band as confirmed by Sanger sequencing.
Lower panel, genotyping PCR of KO allele. D and E,Mut expression amongwt tissues (error bars are S.E.; n 4; *, p 0.01) (D) and KO allele-dependent loss of
Mut expression (bars aremeans normalized towt in each tissue; error bars depict S.E.; n 4; *, p 0.05) (E). F, Western blot analysis of Mut protein levels using
-actin as loading control. The lower band in the top panel of each organ represents an unspecific band. G and H, Mut activity varies by tissue (G) and by
genotype (H) (bars aremean values and in each tissue normalized to thewt value; error bars are S.E.; n 4; *, p 0.0001). Significance levels are the same in all
five tissues (not depicted for clarity).
Phenotype and Treatment Study inMMAuriaMouseModel
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grams, S.D.  0.043 and in Mutko/ki 0.078  0.048). In this
cohort, C3 (normalized to acetylcarnitine (C2)) in blood and
MMA in urine were constantly elevated over the entire time
span investigated (Fig. 2, B and C). Survival was the same in all
three groups (all mice still alive after 1 year except for one
Mutki/ki and one Mutko/ki, both of which died during blood
collection).
To gain further insight into the consequences of the clearly
reduced Mut enzymatic activity, we performed a cross-sec-
tional analysis of hallmark metabolites of MMAuria (18) at 35
days of age. MMA was found elevated in a genetic dosage-de-
pendent manner in tissues, urine and dried blood, with the
highest levels found in Mutko/ki mice (Fig. 2D). Although
Mutki/ki animals showed considerably lower levels, they were
still significantly elevated compared with controls (Fig. 2D). C3
levels (normalized to C2) showed the same trend (Fig. 2E).
Mutki/wt andMutko/wt did not show any elevations, suggesting
that one functional wt allele is sufficient to cope with the
demands of the propionate pathway (Fig. 2,D andE). Ammonia
levels, which are elevated during metabolic crisis in patients,
were normal (Fig. 2F), suggesting that these animals did not
suffer from acute crises on normal chow. Similar to patients
(19–21), both Mutko/ki and Mutki/ki showed elevated glycine
levels (Fig. 2G), whereas other amino acid levels were mostly
unchanged.
In addition to classic metabolites, we performed a compre-
hensive analysis of fatty acids and sphingoid bases. We found
increased levels of odd chain fatty acids, including the 17-car-
bon chain length fatty acid, which has recently been proposed
as a biomarker ofMMAuria (22, 23), with normal levels of even
chain fatty acids (Fig. 2H). Further, we show here for the first
time an elevation of odd chain length sphingoid bases in plasma
(Fig. 2I) and tissues (Fig. 2J), possibly as a consequence of the
increased odd chain fatty acids, whereas levels of even chain
sphingoid bases remained normal (Fig. 2I). Specific fatty acid
and sphingoid base levels are freely available upon request.
Initial Characterization of the Renal and Neurological
Phenotypes—We investigated whether Mutko/ki mice suffer
from similar long term complications as patients with MMAuria,
e.g. renal dysfunction. When normalized to body weight,
Mutko/ki mice consistently produced less urine during adult-
hood than littermate controls (Mutki/wt) (Fig. 3A), although
water intake was not significantly different between the two
groups (Fig. 3B). Consistent with renal dysfunction, these mice
alsohad increasedplasmaurea throughout the timecoursemea-
sured (Fig. 3C), which has been observed in the context of a
FIGURE 2. Clinical and biochemical phenotype of Mutki/ki and Mutko/ki mice (genotypes see legend, data in panels D–J are derived from female
animals). A, monitoring of body weight over time. Decreased body weight in female Mutki/ki mice is significant compared with Mutki/wt from day 162, and in
Mutko/ki significant compared with Mutki/wt from day 114. For both, p 0.05. B, C3 levels in dried blood spots normalized to C2. C, MMA levels measured by
LC-MS/MS in urine collected overnight inmetabolic cages. InA–Cpoints representmean values, error barsdepict S.E. and n 5/group.D, MMA levels in tissues
(left panel), urine (middle panel), and dried blood (right panel), determined by tandem mass spectrometry. E, C3 levels normalized to C2 in dried blood. F,
ammonia levels measured in whole blood. G, glycine concentration determined in dried blood by tandemmass spectrometry. H, fatty acid levels determined
inplasmaandexpressedaspercentageof total fatty acids. I, plasma levels of sphingoidbases (expressedaspmol/l plasma). J, 17-carbon chain sphingoidbase
levels in different tissues expressed as pmol/g protein. D–J, bars represent mean values from 35 days old mice (error bars depict S.D.; n 4; *, p 0.05).
Phenotype and Treatment Study inMMAuriaMouseModel
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decreased glomerular filtration rate (24). Renal tubular dys-
function in these animals was evidenced by disturbed excretion
of several electrolytes in urine (Fig. 3D). Kidney damage was
further supported by increased levels of the biomarker lipoca-
lin-2 (Lcn2) in kidney tissue (Fig. 3E). Of note, lightmicroscopy
examination of hematoxylin-eosin stained sections of kidneys
from Mutki/wt and Mutko/ki mice (female, 1 year old) did not
reveal any structural abnormalities (Fig. 4A).
Neurological dysfunction is the other major long term com-
plication of MMAuria (25, 26), often manifesting as movement
disorder because of lesions in the basal ganglia, and in acute
metabolic crisis brain edema may be observed. In theMutko/ki
mice we observed an increase in brain weight at the age of 1
month as well as 1 year (Fig. 3F), which may be suggestive of
brain edema. Although brain histology was normal in the basal
ganglia (Fig. 4B), we also identified an up-regulation in Lcn2 at
the mRNA and protein level (Fig. 3G). Together, the initial
characterization of both the brain and kidney, in combination
with the metabolites already identified in these organs, suggest
an initial dysfunction in each, which has not yet manifested at
the gross level.
Diet-induced Metabolic Decompensation—An increased
throughput of the propionate pathway in patients withMMAuria,
e.g. caused by a catabolic state or an augmented protein intake,
often results inmetabolic decompensation (crisis). To replicate
this state in our MMAuria mouse models and exacerbate their
clinical phenotype, we used dietary challenge. Mice were fed a
high protein (HP) diet, as used previously (13), or a precursor-
enriched (PE) diet comprised of increased levels of precursor
amino acids of propionate pathway metabolites, i.e. isoleucine,
valine, and threonine. Upon initiation of both diets at the age of
2 months, both Mutko/ki and Mutki/ki mice experienced rapid
weight loss, which was so severe that the study had to be termi-
nated after 3 days (Fig. 5A). The effect exerted by the PE diet
appeared to be stronger than theHP diet, as shown by themore
pronounced weight loss (Fig. 5A), likely reflecting the 2-fold
FIGURE 3. Renal and neurological phenotype. A, urine production measured in metabolic cages overnight and expressed as microliters of urine per hour
normalized to bodyweight. B, overnight water intakemeasured in grams of water normalized to bodyweight. C, urea in plasma expressed inmg per deciliter.
D, electrolytesmeasured in urine and normalized to grams of creatinine. E, Western blot ofMut and Lcn2 in kidney at two different time points. F, brainweight
normalized tobodyweight at threedifferent timepoints.G, expressionof Lcn2 inbrain tissueonmRNA level normalized to-actin andonprotein level (-actin
as loading control). In A–D, F, and G, points and bars represent mean values (error bars depict S.E.; *, p 0.05).
Phenotype and Treatment Study inMMAuriaMouseModel
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higher isoleucine, valine, and threonine content in the PE diet
(70, 84, and 53 g/kg compared with 35, 42, and 27 g/kg, respec-
tively). Brain weight (normalized to bodyweight) was increased
in Mutko/ki mice under both diets, which was not the case on
reference chow (RC: isoleucine, 10 g/kg; valine, 12 g/kg; threo-
nine, 7.6 g/kg) at this age (Fig. 5B). Investigation of the plasma
before and after the diet change revealed, from both diets, fur-
ther elevated levels of MMA, C3, and for the first time in these
mice, increased ammonia levels in Mutki/ki and Mutko/ki mice
(Fig. 5, C–E), consistent with the induction of metabolic crisis.
Further investigation ofMMA and 2-MC concentrations in the
brain, kidney, and liver demonstrated a gene dosage-dependent
increase of both metabolites in mice on either diet, compared
with mice on the control diet (RC) (Fig. 5, F–H). Indeed,
although these metabolites were already elevated in Mutko/ki
and Mutki/ki mice on RC (e.g. brain levels of MMA in Mutko/ki
were 4.4 times higher than inMutki/wt; Fig. 5F), they were fur-
ther increased up to 53-foldwhen the dietwas changed toHPor
PE (Fig. 5F).
Cobalamin Treatment Partly Rescues Diet-induced Meta-
bolic Crisis—To attempt to mitigate the effects exerted by the
HP diet, we treated the mice with daily i.p. injections of OHCbl
(0.3g/g) for aweek before and continuously during the dietary
challenge. These injections resulted in nearly doubled levels of
plasma Cbl (Fig. 6A), indicating efficient uptake of the vitamin
into the blood stream. Mutki/ki mice appeared to be partially
protected by this treatment, as, in contrast to mice on the HP
diet alone (Fig. 5A), OHCbl-treatedMutki/ki mice did not show
significant weight loss (Fig. 6B). Further, elevations in C3 and
ammonia weremarkedly delayed, although they increased con-
siderably, along with MMA, by the study’s end (Fig. 6, C–E).
Mutko/ki mice showed a less obvious but slight protective effect.
Their weight loss was delayed compared with their untreated
counterparts (compare Fig. 5A, HP, and Fig. 6B), and they did
not have the significantly increased brain weight (Fig. 6F) seen
previously (Fig. 5B). However, they did show immediate and
striking increases in metabolite levels (Fig. 6, C–E) suggesting
they remained metabolically compromised.
Discussion
Novel Mouse Models Recapitulate Clinical and Biochemical
Phenotype of MMAuria—In this study, we aimed to generate
novel mouse models of MMAuria that survive through adult-
hood but show clear biochemical and clinical signs of disease.
To achieve thesemodels, we knocked in amissensemutation to
the mouse Mut gene. This constitutive KI allele causes Mut
deficiency, which is further aggravated by combination with a
KO allele. The most striking phenotypic sign in our mice was
growth retardation, which is likely a correlate of failure to thrive
described in human patients (3, 6). This lack of weight gain is
not readily explained by reduced energy intake, because we
identified no difference in overnight food consumption
between the mutant mice and controls, suggesting that other,
possibly subcellular, processes are affected. Previous studies
point toward inhibited tricarboxylic acid cycle enzymes and
interference with oxidative phosphorylation in MMAuria (27–
29). It will be important to assess these potentialmechanisms in
future studies.
Further clinical signs could be observedwhen the diseasewas
accelerated bymeans of a high protein challenge. The success of
this approach was demonstrated by the substantial elevation of
metabolites and immediate loss of body weight in both diets
(HP and PE) for both mouse genotypes (Mutko/ki andMutki/ki),
suggesting that the propionate pathway was unable to process
the additionalmetabolic load contributed by themodified diets.
As indicated by the significantly elevated ammonia levels, this
induced situation is consistent with acute metabolic crisis,
where aggressive treatment is required to prevent encephalop-
athy when ammonia levels rise above a threshold of 200 mol/
liter (30).
Along with these general organism-wide symptoms, we were
able to identify organ-specific disturbances in the kidney and
FIGURE 4.Histological analysis by hematoxylin-eosin staining of kidney (A) andbrain (B) sections fromMutki/wt andMutko/ki femalemice at the ageof
1 year. Scale bars are 10 m in the kidney pictures, 1 mm on brain overview pictures, and 100 m in the insets of the basal ganglia.
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the brain. Under normal diet conditions, adult Mutko/ki mice
showed manifestations of kidney dysfunction, as evidenced by
increased plasma urea, impaired diuresis, and changes in the
urinary excretion of electrolytes. These changes mirror the
organ manifestations of MMAuria patients, in whom chronic
kidney disease occurs in almost half of all cases in an age-de-
pendent manner (3–6). In our mice, these changes were
accompanied by increased renal levels of Lcn2, a protein that
has been suggested to be an early biomarker of chronic kid-
ney damage (31), including in MMAuria (13). Further, we
found increased brain weight in theMutko/ki mice at 1 month
and 1 year of age, possibly indicative of cytotoxic edema as a
sign of neurotoxicity. Interestingly, we also found increased
Lcn2 mRNA and protein levels in the brain of these mice. In
contrast to its potential role as a kidney specific marker,
up-regulation of Lcn2 in the brain has been suggested to be a
biomarker in multiple sclerosis (32) and was found to be
up-regulated in animal models of brain-specific diseases (33,
34). Hence, the specific role of Lcn2 as an organ-specific
biomarker remains unclear; however, the finding of up-reg-
ulation in affected tissues suggests at least a general role in
dysfunctional cells.
Biochemically, the phenotype of human patients was accu-
rately emulated, as illustrated by the types of metabolites that
FIGURE 5.Modified diet leads to disease acceleration.A, start of bothmodified diets at 60 days of age is indicated by the black arrows.Upper panel, PE; lower
panel, HP. Monitoring of body weight showed significant differences among the three groups on day 63 for both diets. B, weight of brain normalized to body
weight after diet study. C, MMA in dried blood.D, C3 (normalized to C2) in dried blood. E, whole blood ammonia before and after diet modification. F–H, MMA
and 2-MC levels in homogenates of brain (F), kidney (G), and liver (H) tissue on RC, HP, and PE as determined byGC-MS. For all panels, from five animals for each
genotype, bars and points represent means; error bars are S.E. For A–E, *, p 0.01; n.s., not significant; statistics were not calculated for F–H.
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were increased and the extent of their elevation. For example,
MMA levels in the urine were detected in a range comparable
with humanmut	 patients (35), whereas glycine, thought to be
increased by inhibition of the intramitochondrial glycine cleav-
age enzyme caused by accumulated organic acids or their CoA
esters (36), was found at high levels in our mice, similar to the
description in the first MMAuria patients (37). Further, we
found elevated levels of odd chain fatty acids, most likely as a
consequence of increased C3, which is used as a primer in fatty
acid synthesis (6, 23, 38, 39). In addition, we present for the first
time elevations of odd-numbered chain sphingoid bases in
plasma and tissue. Their elevation may be explained by the dis-
turbed fatty acid metabolism, i.e. serine palmitoyltransferase, a
key enzyme in sphingoid base synthesis, maymore often utilize
17- or 19-carbon fatty acid CoAs as substrate, instead of the
normally preferred 14- or 18-chain length fatty acids. The
pathophysiological significance of this newly discovered phe-
nomenon remains unknown.
Overall, these novel models of MMAuria recapitulate many
of the biochemical and clinical hallmarks of MMAuria in
patients and thus are excellent tools to study the pathogenesis
of disease. Application of a long termdietary challengewith less
potent dietswill potentially allowmonitoring of chronic disease
progression, leading tomore pronounced impacts on brain and
kidney tissue.
Gene Dose Dependence Allows Titration of Disease Severity—
Patients carrying the p.Met700Lys mutation show an interme-
diate phenotype with relatively late onset and residual enzyme
and pathway activity in fibroblast cell homogenates (15, 16, 40).
Based on these observations, the measurable residual enzyme
activity in vitro, and themissense type of the variant used for the
generation of the KI allele, we expected that the KI allele would
result in a milder phenotype than the KO allele, which is in fact
a truncating mutation. Indeed, a gene dose-dependent effect
was corroborated by all experimental data: Mutko/ki mice dis-
played higher concentrations of MMA, 2-MC, and C3, more
pronounced growth retardation, and a stronger response to
dietary challenge than homozygous Mutki/ki animals. There-
fore, the gene dose effect detected in our study is analogous to
the phenotypic differences observed in patients. This circum-
stance is a true benefit of this study because the novel animal
models allow us to modulate the phenotypic severity of
MMAuria and to systematically assess milder and more severe
forms of MMAuria.
Response to Cobalamin Treatment—It is recommended to
evaluate every mut-type MMAuria patient for responsiveness
to cobalamin treatment (6, 35). However, no systematic study
has thus far investigated the effectiveness of cofactor treat-
ment in mut-type MMAuria. If effective, the cofactor would
be expected to ameliorate disease by supporting the enzyme
activity and/or stability, similar to the cofactor response dis-
played by phenylalanine hydroxylase (41). The human
mutant p.Met700Lys is an excellent candidate to test cobal-
amin responsiveness, because patient fibroblasts compound
heterozygous for this and a premature stop mutation showed
4.5-fold times increased incorporation of [14C]propionate into
acid precipitable material when supplemented with OHCbl
(40), and biochemically this mutation was found to affect the
Km of MUT for AdoCbl (14). Indeed, in our HP diet study,
Mutki/ki mice appear to have been at least partly protected by
pre-administration of OHCbl. These mice did not show the
immediate weight loss associated with the initiation of the HP
FIGURE 6. Treatment of HP diet-induced phenotype by OHCbl. A, cobalamin levels in plasma of untreated mice and OHCbl-treated mice (*, p 0.0001). B,
time course of body weight. The black arrow indicates start of HP diet on day 60. Differences of body weight on day 64 were significant betweenMutko/ki and
the other two genotypes (Mutki/ki andwt), which did not differ significantly from each other. C–E, C3 (normalized to C2) (C), MMA levels in dried blood (D), and
whole blood ammonia levels (E) were measured on the day the diet was started (day 60) and on days 62 and 64 following diet commencement. F, weights of
brain whole organs in sacrificed animals at the end of the study. In B–E duration of HP diet was from days 60 to 64 and OHCbl treatment from days 53 to 64 as
indicated by capped horizontal lines. Points and bars represent mean values; error bars in all panels depict S.E.
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diet and showed delayed accumulation of metabolites. The
reduced degree of protection for Mutko/ki mice suggests that
with the level of Cbl achieved by these injections, both mutant
alleles are required to be potentially Cbl-responsive. An even
better rescuemay be facilitated by the application of higher Cbl
doses in these mice, potentially reaching levels suggested for
treatment in human patients (35). Nevertheless, our results set
the stage for further exploration of cofactor response, a concept
thatmay be applicable tomany othermissensemutations, since
approximately one-quarter of all mut-type mutations show an
in vitro response to cobalamin (3).
Experimental Procedures
InVitro Cell Culture and EnzymeActivity Assay—Constructs
of human (hs) MUTwild-type and mouse (mm)Mut wild-type
and the mutants hs-p.Met700Lys and mm-p.Met698Lys were
made by site-directed mutagenesis in the pTracer-CMV2 vec-
tor (Thermo Fisher Scientific) using the QuikChange site-di-
rected mutagenesis kit (Stratagene) following the manufactu-
rer’s instructions. Constructs were transiently transfected into
immortalized fibroblasts carrying the homozygousMUTmuta-
tion p.Gln30* by electroporation. Cell lysates were obtained by
from frozen, pelleted cells by sonication in 5 mM potassium
phosphate buffer (pH 7.4) and enzymatic activity andKm deter-
mined as previously described (14).
Mouse Tissue Preparation—Liver, kidney, brain, heart, and
muscle as well as blood samples were removed from euthanized
mice and stored at 	80 °C. Lysates of homogenized (TissueLyser
II; Qiagen) tissues were resuspended in 300–600 l of a lysis
buffer dependent on the subsequent usage of the sample, either
buffer A (Triton X-100 0.5% (v/v), 10 mM HEPES at pH 7.4, 2
mMDTT, 1 tablet of Complete Protease InhibitorMixture Tab-
lets; Roche) forWestern blot and activity assay or buffer B (250
mM sucrose, 50 mM KCl, 5 mM MgCl2, 20 mM Tris base,
adjusted to pH 7.4) for determination of MMA and 2-MC lev-
els. The homogenate was then centrifuged at 14,000 rpm for 10
min at 4 °C, and the supernatant was used for MUT activity
assay (14), Western blotting, and quantitative RT-PCR (see
below).
Housing of Mice and Generation of Knock-in Allele—Animal
experiments were performed in accordance with policies of the
VeterinaryOffice of the State of Zurich and Swiss law on animal
protection. Animal studies were approved by theCantonal Vet-
erinary Office Zurich under license number 202/2014. Animals
were kept in single-ventilated cages and under controlled
humidity and temperature (21–23 °C). Whenever possible, lit-
termate controls were used to compare experimental groups.
The generation of mice carrying the Mut-p.Met698Lys
mutation was performed by Polygene (Rümlang, Switzerland)
using embryonic stemcell targeting. To generateMutko/kimice,
female Mutko/wt (7) were crossed to Mutki/ki males. Mouse
genotyping was performed on genomic DNA from ear punch
biopsies using the primers 5-GTGGGTGTCAGCACAC-
TTG-3 (forward) and 5-CGTATGACTGGGATGCCT-3
(reverse) for the ki allele and 5-ACAACTCCTTGTGTAG-
GTC-3 (forward) and 5-CCTTTAGGATGTCATTCTG-3
(reverse) for the ko allele.
Long Term Studies and Metabolic Cage Studies—Long
term monitoring of mice entailed weekly weight measure-
ments and regular blood collections, as well as urine collec-
tions. The animals were single caged overnight to collect
urine and measure individual chow and water intake. Urine
was collected in the morning, the sediment was removed,
and supernatant was frozen at 	80 °C.
Quantitative Real Time PCR Analysis and Western Blot—
Total RNA (QIAmpRNAbloodmini kit; Qiagen)was extracted
from frozen mouse tissue lysates and analyzed for expression
using specific probes for Mut (Mm00485312_m1) and Lcn2
(Mm01324470_m1) via the TaqMan Gene Expression Master
Mix on a 7900HTFast Real-Time PCR System, with normaliza-
tion to -actin (Mm00607939_s1) (all Thermo Fisher Scien-
tific). Experiments were performed in triplicate. For Western
blotting analysis, antibodies against MUT (ab67869, 1:500;
Abcam), Lcn2 (ab63929, 1:1000; Abcam), and -actin (A2228;
Sigma-Aldrich) were detected byHRP-labeled goat anti-mouse
(sc-2302; Santa Cruz) or goat anti-rabbit (sc-2301; Santa Cruz)
IgG at a dilution of 1:5000. Bands were quantified by normal-
ization to internal -actin control bands.
Metabolite Measurements—MMA in mice urine was ana-
lyzed by liquid chromatography mass spectrometry (LC-MS/
MS) on a Thermo Scientific UltiMate 3000 rapid separation
LC coupled to an AB Sciex 5500 TripleQuad mass spectrom-
eter using a commercial kit (Recipe ClinMass advanced).
For determination of the concentrations of amino acids,
acylcarnitines (C2 and C3), as well as MMA in dried blood
spots, blood was collected from tail vein onto a filter card and
dried. Punches from filter cards were analyzed by tandem
mass spectrometry similar to Ref. 42. Total fatty acid profiles
from plasma/serum were determined by direct methylation
and gas chromatography, as described (43). Sphingoid bases
were analyzed in tissue homogenates, as published (44).
Ammonia levels in whole blood were measured by the Pock-
etChem blood ammonia meter (PA-4140; Arkray). Electro-
lytes in urine were measured by a timed end point method
(SYNCHRON system kit; Beckman Coulter). For urea deter-
mination in plasma the SYNCHRON CX3 Delta System was
used (kit no. 443350; Beckman Coulter).
Diet and Cobalamin Therapy—We applied a HP (60% pro-
tein, TD.140830; Harlan) and PE (700% isoleucine, valine and
threonine compared with reference, TD.140829; Harlan) diet
to 60-day-oldmice. For the PE diet, leucine (19 g/kg, 119%) was
enriched because its uptake might compete with the uptake of
the other amino acids, which are increased in the diet, and
cystine was increased (3.5 g/kg, 700%) to elevate the overall
sulfur content. For cobalamin rescue, mice were injected with
0.3 g hydroxocobalamin (Streuli Pharma AG) i.p. 7 days
before and throughout diet treatment.
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